Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
about
Improvement in erythropoieis-stimulating agent-induced pure red-cell aplasia by introduction of darbepoetin-α when the anti-erythropoietin antibody titer declines spontaneously.Potential impact of subsequent entry biologics in nephrology practice in Canada.Emerging patient safety issues under health care reform: follow-on biologics and immunogenicity.Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis.Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatmentLinking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR).Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project.Pure red cell aplasia induced by epoetin zeta.The use of intravenous iron in patients with cancer-related anaemia.Epoetin-associated pure red cell aplasia: past, present, and future considerationsClinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body.Anemia of renal disease: what it is, what to do and what's new.Paradoxical and bidirectional drug effects.Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies-a systematic review.Rituximab: A viable treatment option for epoetin-induced pure red cell aplasia.Successful treatment of a hemodialyzed patient with pure red cell aplasia associated with epoetin beta pegol therapy with cyclosporine.Feasibility of a multiplex flow cytometric bead immunoassay for detection of anti-epoetin alfa antibodies.Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation.Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report.Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease.Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus.A cluster of Epoetin-associated pure red cell aplasia: clinical features and the possible association of HLA-DRB1*12:02.A detailed examination of the antibody prevalence and characteristics of anti-ESA antibodies.Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin.Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP).Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia.
P2860
Q34255699-B470F736-0CBA-4E9A-8673-F75E49DCE551Q35146196-511EF195-62D5-44BA-9701-913B79B72486Q35660768-C4DBD62C-DF10-4119-8B11-59F78D459D43Q35939486-EC743DE7-84A3-4351-9822-4B29CCE98AF7Q36039649-527E7D67-26BD-4DF2-88AD-EBAD05CB9B6CQ36338254-B57C4803-631D-4B23-9BC1-FABBD94B2A2BQ36431597-25C38332-52EF-4699-9543-737BC385328BQ36920523-E199370F-8894-4A0E-9D93-1C02A36CA7BEQ37119052-45692648-47D5-4651-9822-4D6900DEA3AAQ37137958-52476407-12B4-4F9B-8897-C3CDD8E41D34Q37164738-256F3847-F3FC-466F-BDAB-4F32F04704AEQ37700537-F9002A89-1E56-4F8A-8FD3-76E3A5F2E3B5Q37923100-DF2A3042-0414-47B4-A76E-ACA9C60F4B6FQ37978338-72280537-D74E-42B5-A36A-D5360DC2B59DQ38904887-C73CD388-D7BC-4CCA-87F1-D59F5E0F0395Q41783729-822C4713-6808-48B3-89FD-DDB77621A6EFQ41821604-48B6293C-C5DF-4293-BBE4-96E279200464Q41954237-C32D2283-A185-4D9E-93D2-2B5439D9929BQ42239843-F853B56C-1A59-489A-9479-CF64FB0B083CQ42545704-77395B42-DFF1-4DF6-8439-9708AAD77447Q47111895-3D09ABC2-4260-44F1-9531-4AFDE5B24BB7Q48188060-154B089A-5E8D-4E87-B08C-FA4259071FF4Q50236570-0765D9F1-B314-40DF-879E-FE2AEBCEA559Q50501091-0C86ED6E-9D4F-42E3-B270-10AE057D9848Q50533140-9810B709-5B8C-424A-AC5C-509CD122AD92Q50627188-FECE23E9-CF3B-45B4-9696-240C26CEDAF2Q50654749-52A3CF4E-2096-4CB9-9DDB-AF469E427F50
P2860
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Long-term outcome of individua ...... ts and Reports (RADAR) Project
@ast
Long-term outcome of individua ...... ts and Reports (RADAR) Project
@en
type
label
Long-term outcome of individua ...... ts and Reports (RADAR) Project
@ast
Long-term outcome of individua ...... ts and Reports (RADAR) Project
@en
prefLabel
Long-term outcome of individua ...... ts and Reports (RADAR) Project
@ast
Long-term outcome of individua ...... ts and Reports (RADAR) Project
@en
P2093
P2860
P50
P1433
P1476
Long-term outcome of individua ...... ts and Reports (RADAR) Project
@en
P2093
Allen Nissenson
Benjamin Kim
Charles L Bennett
Denis Cournoyer
Dennis W Raisch
E Alison Lyons
Edwin B Toffelmire
Francesco Locatelli
George A Wells
Hans A Messner
P2860
P304
P356
10.1182/BLOOD-2005-02-0508
P407
P577
2005-08-11T00:00:00Z